Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFAMOSI
2019-002197-31Phase 4Active
- Sponsor
- University Medical Center Mainz
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Afatinib followed by osimertinib with Osimertinib (2 arms). Primary endpoint: Time to EGFR-TKI failure within 24 months. Started Sep 2019; status: active.
02
Drugs
afatinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2019-002197-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002197-31.